Dr Baik is a head and neck cancer and reconstructive surgeon. He studied Biology at the University of Pennsylvania and went on to receive his medical training at UC San Diego. After completing his residency in Otolaryngology at the University of Washington, he pursued advanced training in Head and Neck Oncology and Reconstructive Surgery at Mount Sinai Beth Israel Hospital in New York City.

His primary focus is to provide surgical care for patients with head and neck cancer, specifically squamous cell carcinoma and melanoma.

His research is focused on precision diagnostics to aid pre-operative and intra-operative decision making. He is interested in improving cancer detection using labeled and un-labeled imaging techniques combined with machine learning algorithms.

Clinical Focus

  • Head and Neck cancer
  • Microvascular Reconstruction of the Head and Neck
  • Skin cancer
  • Melanoma
  • Otolaryngology

Academic Appointments

  • Assistant Professor - Med Center Line, Otolaryngology - Head & Neck Surgery Divisions

Professional Education

  • Fellowship:Icahn School of Medicine at Mount Sinai Head and Neck Oncology Fellowship (2018) NY
  • Board Certification: Otolaryngology, American Board of Otolaryngology (2018)
  • Fellowship, Mount Sinai Beth Israel Hospital, New York, Head and Neck Oncologic & Reconstructive Surgery (2018)
  • Residency, University of Washington, Otolaryngology - Head and Neck Surgery (2017)
  • MD, University of California, San Diego, Medicine (2011)
  • MAS, University of California, San Diego, Clinical research (2010)
  • BA, University of Pennsylvania, Biology (2005)


All Publications

  • Combined mandibular and maxillary reconstruction: Managing sinus secretions and preventing infection. The Laryngoscope Baik, F. M., Yue, L. E., Sharif, K. F., Sims, J. R., Urken, M. L. 2019

    View details for PubMedID 30667067

  • Gorilla endoscopic sinus surgery: a life-saving collaboration between human and veterinary medicine INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY Davis, G. E., Baik, F. M., Liddell, R. M., Ayars, A. G., Branch, K. R., Pottinger, P. S., Hillel, A. D., Helmick, K., Collins, D. 2018; 8 (7): 857?62


    Chronic rhinosinusitis is a common disease process in humans; however, in the primate population of gorillas, it has rarely been described. This case describes lifesaving sinus surgery on a critically ill gorilla performed by a human otolaryngology team in collaboration with the gorilla's veterinary medicine team.The 35-year-old western silverback gorilla was treated for 3 months with aggressive medical therapy for a worsening sinus infection. When his condition became severe, a computed tomography (CT) scan was performed showing advanced chronic rhinosinusitis with nasal polyps vs other masses and some bone erosion. As his condition deteriorated further, a tertiary otolaryngology team performed sinus surgery using the latest technology available, including image guidance, steroid-eluting sinus stents, and balloon sinus dilation. The postoperative course was complicated by subcutaneous infection and eventual fistulization. Fortunately, with culture-directed antibiotic therapy his condition gradually improved. One year later he required revision sinus surgery. At that point allergy testing was performed followed by appropriate allergy medical therapy. Now, 3 years out from his initial surgery, he continues to do well and has fathered a young female gorilla.This case represents a unique collaboration between human physicians and veterinarians. The combined medical approach was critical to heal this ailing gorilla. This case discusses many of the challenges and offers recommendations for physicians who may be involved with similar care of animals in the future.The success of the surgical and medical treatment of this gorilla's life-threatening sinus infection required many experts, careful planning, and corporate generosity. The interaction between human and animal medicine would not have been successful without the close and trusting collaborations between human and veterinary health providers. We encourage human healthcare providers to seek volunteer opportunities through their local zoos by engaging in discussions with their local veterinarians.

    View details for PubMedID 29569338

  • Septic arthritis of the sternoclavicular joint: A unique late complication after tracheostomy. American journal of otolaryngology Sharif, K. F., Baik, F. M., Jategaonkar, A. A., Khorsandi, A. S., Urken, M. L. 2018; 39 (5): 646?48


    Septic arthritis of the sternoclavicular joint is a rare infection associated with significant morbidity and mortality. Several risk factors for septic arthritis have been reported in the literature ranging from immunodeficiency to intravenous drug use.A 63-year-old male previously treated for synchronous squamous cell carcinomas of the epiglottis and floor of mouth presented with tenderness and swelling of the sternoclavicular joint two months after tracheostomy decannulation. Computed tomography and bone scans confirmed the diagnosis of septic arthritis of the sternoclavicular joint. The patient's clinical course, surgical treatment, and management considerations are discussed here.Septic arthritis of the SCJ is a rare but serious infection. Once diagnosed, septic arthritis of the SCJ should be promptly treated to prevent further morbidity and mortality.

    View details for DOI 10.1016/j.amjoto.2018.05.005

    View details for PubMedID 29776683

  • Airway management for symptomatic benign thyroid goiters with retropharyngeal involvement: Need for a surgical airway with report of 2 cases Otolaryngology Case Reports Baik, F. M., Zhu, V., Patel, A., Urken, M. L. 2018; 7 (C): 10-12
  • A rare primary leiomyosarcoma of the parotid gland: A case report and literature review. American journal of otolaryngology Yue, L. E., Qazi, M., Kiplagat, K., Baik, F. M., Khorsandi, A., Brandwein-Weber, M., Urken, M. 2018; 39 (3): 345?48


    Leiomyosarcoma of the head and neck region is very rare. Primary parotid leiomyosarcoma has only been reported nine times in the medical literature.A 68-year-old female presented with a left facial mass. Physical examination revealed a firm immobile mass at the level of the left parotid tail. No facial nerve dysfunction or palpable adenopathy was noted at the time of presentation. This patient underwent a superficial parotidectomy with a facial nerve dissection and left selective neck dissection.Pathologic findings revealed a sarcoma of intermediate to high-grade, composed of spindle cells with herringbone pattern, eosinophilic fibrillary cytoplasm, and focal granularity. Immunohistochemistry was positive for vimentin and smooth muscle actin and negative for desmin, S100 and CD34. The findings are consistent with a leiomyosarcoma. Following complete surgical resection, adjuvant radiation therapy was administered.Primary sarcomas of the parotid gland, specifically parotid leiomyosarcomas, are extremely rare. Based on this patient's tumor size, grade and resectability, this case met the criteria for a primary leiomyosarcoma. We present only the tenth case of a primary parotid leiomyosarcoma to be reported in the English literature.

    View details for PubMedID 29395283

  • Survival and Gastrostomy Prevalence in Patients With Oropharyngeal Cancer Treated With Transoral Robotic Surgery vs Chemoradiotherapy JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY Sharma, A., Patel, S., Baik, F. M., Mathison, G., Pierce, B. G., Khariwala, S. S., Yueh, B., Schwartz, S. M., Mendez, E. 2016; 142 (7): 691?97


    Treatment of oropharyngeal squamous cell carcinoma (OPSCC) presents unique challenges and can be associated with significant morbidity. Transoral robotic surgery (TORS) has emerged as a treatment modality for OPSCC, but data comparing outcomes between patients treated with TORS-based therapy and nonsurgical therapy are limited.To compare survival and gastrostomy prevalence between patients with OPSCC treated with TORS-based therapy and those treated with nonsurgical therapy.This retrospective matched-cohort study identified patients with OPSCC treated at the University of Washington and University of Minnesota tertiary care medical centers from January 1, 2005, to December 31, 2013. Each patient treated with TORS-based therapy was matched by stage with as many as 3 patients treated with nonsurgical therapy. Final follow-up was completed on April 1, 2015.Disease-free survival, overall survival, and gastrostomy tube prevalence.One hundred twenty-seven patients met the study criteria (113 men [89.0%]; 14 women [11.0%]; median [interquartile range] age, 57 [52-63] years); 39 patients who underwent TORS were matched to 88 patients who underwent nonsurgical therapy. Compared with the nonsurgical group, more patients had p16-positive tumors in the TORS group (30 of 31 [96.8%] vs 30 of 37 [81.1%] among patients with known p16 status). No statistically significant difference in survival between treatment groups was found in multivariable analysis (disease-free survival hazard ratio, 0.22; 95% CI, 0.04-1.36; P?=?.10). Patients who received TORS-based therapy had lower gastrostomy tube prevalence after treatment (13 of 39 [33.3%] vs 74 of 88 [84.1%]) for a univariable relative risk of 0.43 (95% CI, 0.27-0.67; P?

    View details for PubMedID 27347780

  • Fluorescence Identification of Head and Neck Squamous Cell Carcinoma and High-Risk Oral Dysplasia With BLZ-100, a Chlorotoxin-Indocyanine Green Conjugate (vol 142, pg 330, 2016) JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY Baik, F. M., Hansen, S., Knoblaugh, S. E., Sahetya, D., Mitchell, R. M., Xu, C., Olson, J. M., Parrish-Novak, J., Mendez, E. 2016; 142 (5): 505
  • Fluorescence Identification of Head and Neck Squamous Cell Carcinoma and High-Risk Oral Dysplasia With BLZ-100, a Chlorotoxin-Indocyanine Green Conjugate JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY Baik, F. M., Hansen, S., Knoblaugh, S. E., Sahetya, D., Mitchell, R. M., Xu, C., Olson, J. M., Parrish-Novak, J., Mendez, E. 2016; 142 (4): 330?38


    Surgical cure of head and neck squamous cell carcinoma (HNSCC) remains hampered by inadequately resected tumors and poor recognition of lesions with malignant potential. BLZ-100 is a chlorotoxin-based, tumor-targeting agent that has not yet been studied in HNSCC.To evaluate BLZ-100 uptake in models of HNSCC and oral dysplasia.This was an observational study (including sensitivity and specificity analysis) of BLZ-100 uptake in an orthotopic xenograft mouse model of HNSCC and a carcinogen-induced dysplasia model of hamster cheek pouches.Various HNSCC xenografts were established in the tongues of NOD-scid IL2Rgammanull (NSG) mice. BLZ-100 was intravenously injected and fluorescence uptake was measured. To induce dysplasia, the carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) was applied to the cheek pouch of Golden Syrian hamsters for 9 to16 weeks. BLZ-100 was subcutaneously injected, and fluorescence uptake was measured.The signal-to-background ratio (SBR) of BLZ-100 was measured in tumor xenografts. To calculate the sensitivity and specificity of BLZ-100 uptake, a digital grid was placed over tissue sections and correlative histologic sections to discretely measure fluorescence intensity and presence of tumor; a receiver operating characteristic (ROC) curve was then plotted. In the hamster dysplasia model, cheeks were graded according to dysplasia severity. The SBR of BLZ-100 was compared among dysplasia grades.In HNSCC xenografts, BLZ-100 demonstrated a mean (SD) SBR of 2.51 (0.47). The ROC curve demonstrated an area under the curve (AUC) of 0.89; an SBR of 2.50 corresponded to 92% sensitivity and 74% specificity. When this analysis was focused on the tumor and nontumor interface, the AUC increased to 0.97; an SBR of 2.50 corresponded to 95% sensitivity and 91% specificity. DMBA treatment of hamster cheek pouches generated lesions representing all grades of dysplasia. The SBR of high-grade dysplasia was significantly greater than that of mild-to-moderate dysplasia (2.31 [0.71] vs 1.51 [0.34], P?=?.006).BLZ-100 is a sensitive and specific marker of HNSCC and can distinguish high-risk from low-risk dysplasia. BLZ-100 has the potential to serve as an intraoperative guide for tumor margin excision and identification of premalignant lesions.

    View details for PubMedID 26892902

    View details for PubMedCentralID PMC4972605

  • Identification of High-Risk Plaques by MRI and Fluorescence Imaging in a Rabbit Model of Atherothrombosis. PloS one Hua, N., Baik, F., Pham, T., Phinikaridou, A., Giordano, N., Friedman, B., Whitney, M., Nguyen, Q. T., Tsien, R. Y., Hamilton, J. A. 2015; 10 (10): e0139833


    The detection of atherosclerotic plaques at risk for disruption will be greatly enhanced by molecular probes that target vessel wall biomarkers. Here, we test if fluorescently-labeled Activatable Cell Penetrating Peptides (ACPPs) could differentiate stable plaques from vulnerable plaques that disrupt, forming a luminal thrombus. Additionally, we test the efficacy of a combined ACPP and MRI technique for identifying plaques at high risk of rupture.In an atherothrombotic rabbit model, disrupted plaques were identified with in vivo MRI and co-registered in the same rabbit aorta with the in vivo uptake of ACPPs, cleaved by matrix metalloproteinases (MMPs) or thrombin. ACPP uptake, mapped ex vivo in whole aortas, was higher in disrupted compared to non-disrupted plaques. Specifically, disrupted plaques demonstrated a 4.5~5.0 fold increase in fluorescence enhancement, while non-disrupted plaques showed only a 2.2~2.5 fold signal increase. Receiver operating characteristic (ROC) analysis indicates that both ACPPs (MMP and thrombin) show high specificity (84.2% and 83.2%) and sensitivity (80.0% and 85.7%) in detecting disrupted plaques. The detection power of ACPPs was improved when combined with the MRI derived measure, outward remodeling ratio.Our targeted fluorescence ACPP probes distinguished disrupted plaques from stable plaques with high sensitivity and specificity. The combination of anatomic, MRI-derived predictors for disruption and ACPP uptake can further improve the power for identification of high-risk plaques and suggests future development of ACPPs with molecular MRI as a readout.

    View details for DOI 10.1371/journal.pone.0139833

    View details for PubMedID 26448434

    View details for PubMedCentralID PMC4598148

  • Upper Aerodigestive Magnetic Foreign Bodies in Children LARYNGOSCOPE Brown, J. C., Baik, F. M., Ou, H. C., Otjen, J. P., Parish, H. G., Chan, D. K. 2014; 124 (6): 1481?85


    Small, powerful magnets are increasingly available in toys and other products, and are responsible for increasing numbers of foreign body injuries in children. Small, spherical, neodymium magnets available since 2008 are of particular concern. We aimed to identify all cases of upper aerodigestive foreign bodies at our institution over 15.5 years of study.Case series including all patients treated at an urban, tertiary care children's hospital who had upper aerodigestive magnetic foreign bodies, from January 1, 1998 through April 30, 2013.We manually reviewed 7,049 patient records abstracted from billing data to identify all patients 0 to 20 years of age who had upper aerodigestive magnetic foreign bodies.We identified four cases of upper aerodigestive magnetic foreign bodies, one involving the hypopharynx, and three involving the upper esophagus. Three occurred in 2010 or later. Two cases involve the ingestion of multiple, spherical, neodymium magnets recently marketed as desktop toys. In both of these cases, there was a rapid development of mucosal injury at the site of attraction between two magnets.As small, powerful magnets become more ubiquitous, pediatric magnet foreign body injuries are increasing. Although most are gastrointestinal, we identified four recent cases involving the upper aerodigestive tract. Multiple magnets lodged in the hypopharynx or esophagus can rapidly cause pressure necrosis of mucosal tissues, and merit prompt management. Education regarding magnet safety and improved magnet safety standards are needed to reduce the risk of these injuries.4.

    View details for PubMedID 24391087

  • A Large Juvenile Xanthogranuloma within the Tongue OTOLARYNGOLOGY-HEAD AND NECK SURGERY Baik, F. M., Andeen, N. K., Schmechel, S. C., Futran, N. D. 2014; 150 (2): 332?33

    View details for PubMedID 24326868

  • In vivo fluorescence imaging of atherosclerotic plaques with activatable cell-penetrating peptides targeting thrombin activity. Integrative biology : quantitative biosciences from nano to macro Olson, E. S., Whitney, M. A., Friedman, B., Aguilera, T. A., Crisp, J. L., Baik, F. M., Jiang, T., Baird, S. M., Tsimikas, S., Tsien, R. Y., Nguyen, Q. T. 2012; 4 (6): 595?605


    Thrombin and other coagulation enzymes have been shown to be important during atherosclerotic disease development. Study of these proteases is currently limited because of lack of robust molecular imaging agents for imaging protease activity in vivo. Activatable cell penetrating peptides (ACPPs) have been used to monitor MMP activity in tumors and, in principle, can be modified to detect other proteases. We have developed a probe that incorporates the peptide sequence DPRSFL from the proteinase activated receptor 1 (PAR-1) into an ACPP and shown that it is preferentially cleaved by purified thrombin. Active thrombin in serum cleaves DPRSFL-ACPP with >90% inhibition by lepirudin or argatroban. The DPRSFL-ACPP cleavage product accumulated in advanced atherosclerotic lesions in living mice, with 85% reduction in retention upon pre-injection of mice with hirudin. Uptake of the ACPP cleavage product was highest in plaques with histological features associated with more severe disease. Freshly resected human atheromas bathed in DPRSFL-ACPP retained 63% greater cleavage product compared to control ACPP. In conclusion, DPRSFL-ACPP can be used to study thrombin activity in coagulation and atherosclerosis with good spatial and temporal resolution. Thrombin-sensitive ACPPs may be developed into probes for early detection and intraoperative imaging of high risk atherosclerotic plaques.

    View details for DOI 10.1039/c2ib00161f

    View details for PubMedID 22534729

    View details for PubMedCentralID PMC3689578

  • Comparative Case Series of Exostoses and Osteomas of the Internal Auditory Canal ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY Baik, F. M., Nguyen, L., Doherty, J. K., Harris, J. P., Mafee, M. F., Nguyen, Q. T. 2011; 120 (4): 255?60


    Exostoses and osteomas are benign bony lesions of the auditory canal. Although common in the external auditory canal, they are rare and difficult to distinguish in the internal auditory canal (IAC). In this literature review and case presentation, we define radiologic and histologic criteria to differentiate exostoses from osteomas of the IAC. Two patients with exostoses and 1 patient with an osteoma of the IAC are described here. Patient 1 presented with disabling vertigo and was found to have bilateral exostoses with nerve impingement on the right. After removal of the right-sided exostoses via retrosigmoid craniotomy, the patient had complete resolution of her symptoms over 1 year. Patient 2 presented with bilateral pulsatile tinnitus and vertigo and was found to have bilateral IAC exostoses. Patient 3 presented with hearing loss and tinnitus, and a unilateral IAC osteoma was ultimately discovered. Because of the mild nature of their symptoms, patients 2 and 3 were managed without surgery. We show that IAC osteomas can be differentiated from exostoses by radiographic evidence of bone marrow in high-resolution computed tomography scans, or by the presence of fibrovascular channels on histologic analysis. Management of these rare entities is customized on the basis of patient symptoms.

    View details for DOI 10.1177/000348941112000407

    View details for Web of Science ID 000289760500008

    View details for PubMedID 21585156

  • Inverting papilloma of the temporal bone: case report and meta-analysis of risk factors. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology Shen, J., Baik, F., Mafee, M. F., Peterson, M., Nguyen, Q. T. 2011; 32 (7): 1124?33


    To review the literature on inverting papilloma of the middle ear and mastoid with a focus on familiarizing clinicians with its presentation and cause and to discuss its epidemiologic, diagnostic, and therapeutic issues.Search of the English literature for cases of inverted papilloma of temporal bone in conjunction with 1 new case presenting at the UCSD Medical Center.Academic, tertiary referral hospital.The patient underwent radical mastoidectomy with adjuvant therapy, revealing substantial tumor growth filling the external ear canal and middle ear space and obliterating much of the mastoid air cells. Histopathology confirmed inverted papilloma of the middle ear and mastoid. The patient underwent postoperative radiation and has been free of the disease at 6 months of follow-up.A total of 25 inverted papillomas of the temporal bone cases from the English literature between 1987 and 2010 were reviewed. This tumor commonly presents with hearing loss and otorrhea. Although rare, temporal inverted papillomas display a higher incidence of malignancy (40%) compared with sinonasal papillomas. Secondary and recurrent temporal disease was frequently associated with carcinomatous changes. Although recurrence rate is higher in temporal inverted papillomas than that in sinonasal disease, this difference becomes magnified in cases with more aggressive surgical approaches. We present a case of multicentric inverted papillomas in the middle ear and the sinonasal cavities.Efforts to define the cause of middle ear papilloma have been challenging because of its exceeding rarity. Although published literature shows that middle ear papillomas differ from their sinonasal counterparts pathologically and epidemiologically, these papillomas parallel in the unique characteristics of local aggressiveness, tendency to recur, association with malignancy, and multicentricity. Surgical resection with adjuvant radiation therapy and long-term follow-up with magnetic resonance imaging is advocated in the successful management of middle ear inverted papillomas.

    View details for DOI 10.1097/MAO.0b013e31822a2b16

    View details for PubMedID 21817933

  • Exostoses and Osteomas of the Internal Auditory Canal Nguyen, L. T., Baik, F. M., Doherty, J. K., Harris, J. P., Nguyen, Q. T. WILEY-BLACKWELL. 2010: S215

    View details for DOI 10.1002/lary.21682

    View details for Web of Science ID 000286438600091

    View details for PubMedID 21225813

  • An assessment of various blood collection and transfer methods used for malaria rapid diagnostic tests. Malaria journal Luchavez, J., Lintag, M. E., Coll-Black, M., Baik, F., Bell, D. 2007; 6: 149


    Four blood collection and transfer devices commonly used for malaria rapid diagnostic tests (RDTs) were assessed for their consistency, accuracy and ease of use in the hands of laboratory technicians and village health workers.Laboratory technicians and village health workers collected blood from a finger prick using each device in random order, and deposited the blood either on filter paper or into a suitable casette-type RDT. Consistency and accuracy of volume delivered was determined by comparing the measurements of the resulting blood spots/heights with the measurements of laboratory-prepared pipetted standard volumes. The effect of varying blood volumes on RDT sensitivity and ease of use was also observed.There was high variability in blood volume collected by the devices, with the straw and the loop, the most preferred devices, usually transferring volumes greater than intended, while the glass capillary tube and the plastic pipette transferring less volume than intended or none at all. Varying the blood volume delivered to RDTs indicated that this variation is critical to RDT sensitivity only when the transferred volume is very low.None of the blood transfer devices assessed performed consistently well. Adequate training on their use is clearly necessary, with more development efforts for improved designs to be used by remote health workers, in mind.

    View details for DOI 10.1186/1475-2875-6-149

    View details for PubMedID 18001481

    View details for PubMedCentralID PMC2194690

  • Regulation of TNF mediated antiapoptotic signaling in human neutrophils: role of delta-PKC and ERK1/2. Journal of leukocyte biology Kilpatrick, L. E., Sun, S., Mackie, D., Baik, F., Li, H., Korchak, H. M. 2006; 80 (6): 1512?21


    TNF is implicated in the suppression of neutrophil apoptosis during sepsis. Multiple signaling pathways are involved in TNF-mediated antiapoptotic signaling; a role for the MAP kinases (MAPK), ERK1/2, and p38 MAPK has been suggested. Antiapoptotic signaling is mediated principally through TNF receptor-1 (TNFR-1), and the PKC isotype-delta (delta-PKC) is a critical regulator of TNFR-1 signaling. delta-PKC associates with TNFR-1 in response to TNF and is required for NFkappaB activation and inhibition of caspase 3. The role of delta-PKC in TNF-mediated activation of MAPK is not known. The purpose of this study was to determine whether the MAPK, ERK1/2, and p38 MAPK are involved in TNF antiapoptotic signaling and whether delta-PKC is a key regulator of MAPK activation by TNF. In human neutrophils, TNF activated both p38 MAPK and ERK1/2 principally via TNFR-1. The MEK1/2 inhibitors PD098059 and U0126, but not the p38 MAPK inhibitor SB203580, decreased TNF antiapoptotic signaling as measured by caspase 3 activity. A specific delta-PKC antagonist, V1.1delta-PKC-Tat peptide, inhibited TNF-mediated ERK1/2 activation, but not p38 MAPK. ERK1/2 inhibition did not alter recruitment of delta-PKC to TNFR-1, indicating delta-PKC is acting upstream of ERK1/2. In HL-60 cells differentiated to a neutrophilic phenotype, delta-PKC depletion by delta-PKC siRNA resulted in inhibition of TNF mediated ERK1/2 activation but not p38 MAPK. Thus, ERK1/2, but not p38 MAPK, is an essential component of TNF-mediated antiapoptotic signaling. In human neutrophils, delta-PKC is a positive regulator of ERK1/2 activation via TNFR-1 but has no role in p38 MAPK activation.

    View details for DOI 10.1189/jlb.0406284

    View details for PubMedID 17138860

Footer Links:

Stanford Medicine Resources: